PERSPECTA

News from every angle

← Back to headlines

NRx Pharmaceuticals Targets KETAFREE Approval by 2026, Outlines SPARC-TMS Trial

NRx Pharmaceuticals is aiming for KETAFREE approval by 2026 and has outlined a SPARC-TMS trial involving 400 patients, which is backed by military funding.

18 Aug, 15:03 — 18 Aug, 15:03
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed2h ago

NRx targets 2026 KETAFREE approval and outlines SPARC-TMS trial in 400 patients backed by military funding

Read full article →

Related Stories

Meta Faces Landmark Lawsuit Over Youth Social Media Addiction

26m ago

American Airlines Reintroduces Seatback Screens and Expands First Class

35m ago

Apple Alters App Store Rules in EU Following Antitrust Ruling

48m ago

Apple Accidentally Leaks Video of New AirPods with Camera in macOS

1h ago